Real-world outcomes for incidental interstitial lung abnormalities diagnosed over the baseline round of the Yorkshire Lung Screening Trial.
S. Upperton (Leeds, United Kingdom), C. Bradley (Craigavon, United Kingdom), P. Beirne (Leeds, United Kingdom), B. Bhartia (Leeds, United Kingdom), A. Boland (Leeds, United Kingdom), P. Crosbie (Manchester, United Kingdom), M. Darby (Leeds, United Kingdom), R. Gabe (London, United Kingdom), M. Kennedy (Leeds, United Kingdom), T. Sutherland (Leeds, United Kingdom), M. Callister (Leeds, United Kingdom)
Source: International Congress 2022 – How to prevent progression in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Upperton (Leeds, United Kingdom), C. Bradley (Craigavon, United Kingdom), P. Beirne (Leeds, United Kingdom), B. Bhartia (Leeds, United Kingdom), A. Boland (Leeds, United Kingdom), P. Crosbie (Manchester, United Kingdom), M. Darby (Leeds, United Kingdom), R. Gabe (London, United Kingdom), M. Kennedy (Leeds, United Kingdom), T. Sutherland (Leeds, United Kingdom), M. Callister (Leeds, United Kingdom). Real-world outcomes for incidental interstitial lung abnormalities diagnosed over the baseline round of the Yorkshire Lung Screening Trial.. 2659
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|